Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

AngioDynamics (ANGO) reported stronger-than-expected Q4 fiscal 2025 revenue and a narrower adjusted loss, largely driven by its NanoKnife product line, which benefits from FDA clearance, increasing disposable sales, and anticipated reimbursement catalysts for prostate and pancreatic procedures in 2026-2027. This, coupled with growth in Auryon and AlphaVac, has propelled the stock to a 16.3% YTD gain. However, significant tariff impacts on Med Tech and Med Device margins, alongside negative revisions to fiscal 2026 loss estimates, present notable profitability challenges.

Analysis

AngioDynamics (ANGO) presents a dual narrative of strong top-line momentum juxtaposed with significant profitability headwinds. The company delivered a stronger-than-expected fourth-quarter fiscal 2025, beating revenue estimates and reporting a narrower adjusted loss per share, which has contributed to its 16.3% year-to-date share price gain. Growth is underpinned by a diversified portfolio, including Auryon, which posted its 16th consecutive quarter of double-digit growth, and the flagship NanoKnife platform. While NanoKnife's total fiscal 2025 revenue was flat, the 9.6% growth in its recurring disposable sales signals a stable, high-margin revenue stream. Future growth is heavily dependent on key catalysts, including the successful PRESERVE trial meeting its primary endpoints and the anticipated CPT Category I reimbursement codes for prostate and pancreatic procedures in 2026 and 2027, respectively. However, these positives are offset by material margin pressure from tariffs, which compressed Med Tech margins from 62.1% to 59% in Q4. This headwind is fully baked into a cautious fiscal 2026 guidance, projecting an adjusted EBITDA of only $3.0 million to $8.0 million. This profitability concern is further underscored by a negative trend in analyst estimates, with the consensus loss for fiscal 2026 widening to $0.30 per share.

Key Decisions for Investors

• Investors should monitor upcoming reimbursement milestones for NanoKnife, specifically the CPT code implementations in 2026 and 2027, as these are the most significant catalysts for unlocking the platform's long-term earnings potential.
• It is critical to scrutinize gross and EBITDA margins in subsequent quarters to gauge the impact of tariffs, as the guided adjusted EBITDA of $3.0-$8.0 million for fiscal 2026 suggests profitability remains a primary risk despite revenue growth.
• Given the stock's 16.3% year-to-date outperformance against a backdrop of negative earnings revisions and persistent margin pressure, a neutral stance may be warranted until there is clearer evidence that operational efficiencies can offset tariff impacts and drive bottom-line improvement.